Cytarabine shortage yields "inadequate options;" Teva pulls disintegrating reflux tablets;

> "Never in my 30 years of treating patients with leukemia has such a drug shortage occurred [that of cytarabine], resulting in inadequate therapeutic options for patients,"says Hagop Kantarjian, leukemia department chair, MD Anderson Cancer Center. Op-ed

> Teva has withdrawn from distribution its disintegrating tablet form of lansoprazole--a knockoff of the acid reflux drug Prevacid--following an FDA warning to doctors about reports of clogged feeding tubes and blocked syringes linked to tablets that may not have dissolved properly. Letter

> Novartis is likely to continue to streamline operations, with more actions like the recent staff reductions at its Horsham site in the UK. Column

> A musty odor is again cited by a J&J unit in a product recall, this time for the anti-seizure drug, Topamax. Story

> Pharmatek has earned the approval of the U.S. Drug Enforcement Agency for analyzing Schedule I through V controlled substances and conducting stability tests. Pharmatek release

> Cherwell Laboratories will open a manufacturing and warehousing facility for microbiological media. Item

> Kazakhstan is encouraging India on the set-up of joint-venture pharma manufacturing plants and other industrial projects in the former Soviet republic. Statement

> PharmStar Pharmaceuticals is negotiating the purchase a three-acre site and 24,000-square-foot building in Wilson, NC, for production of the OTC liquid pain reliever Aquaprin. PharmStar release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.